LEMAITRE VASCULAR INC — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
LeMaitre Vascular reported Q3 2026 net sales of $68.0M (+11% YoY, +12% organic), with gross margin 71.7% and operating income $17.7M. On October 2026, the company acquired certain vascular assets from B. Braun for $19.2M, including polyester/silver-coated grafts, valve cutters, and vein strippers that generated $9.4M in 2025 sales outside North America; revenue will transition over 18–24 months as B. Braun contracts transfer. For full-year 2026, management guidance raised to $275.8M sales midpoint (+11% organic) and $2.80 EPS midpoint (+18% adjusted), with quarterly dividend increased to $0.25/share and $100M share repurchase program active through February 2027.
Why this rating
B. Braun acquisition ($19.2M) is 1.1% of company market cap; $9.4M annual acquired revenue is 3.5% of LeMaitre's run-rate. Organic growth +12% and margin expansion are solid but not transformational. Routine quarterly dividend and buyback continuation. Moderate positive development, not material to trajectory.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.